Vutrisiran, a transthyretin-directed small interfering RNA therapeutic, is currently approved under the brand name Amvuttra ® for the treatment of polyneuropathy manifestations of hereditary ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced. Offering patients near-complete TTR ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Since then, awareness of ATTR amyloidosis with cardiomyopathy has grown, driving sales of tafamidis and boosting estimates of disease prevalence. Worldwide tafamidis sales last year reached $3.3 ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

This clearance makes EchoGo ® Amyloidosis the first commercially available software-only medical device to facilitate detection of Cardiac Amyloidosis using echocardiography. Requiring a single ...

ATTR amyloidosis results from the buildup of ... Both hATTR and ATTRwt increase your risk of cardiomyopathy and heart failure. However, neuropathy (a problem with your nervous system) is a common ...

Cardiac Amyloidosis is an infiltrative cardiomyopathy in which abnormal ... requiring only a single apical 4-chamber echo video clip. Ultromics' medical devices are software-only, manufactured ...